Cartesian Therapeutics Interest Coverage
The Interest Coverage Ratio of Cartesian Therapeutics (RNAC) as of Oct 13, 2026 is -88.50. In the previous year, Interest Coverage Ratio was -0.59 — a change of 14,998.99% (lower).
Get this data via API
Financial Data API
Interest Coverage
-88.50
YoY
14,998.99%
Last updated:
The Cartesian Therapeutics Interest Coverage history
3 Years
10 Years
25 Years
Max
| YEAR | Interest Coverage | YoY |
|---|---|---|
| -88.50 | +14,998.99% | |
| -0.59 | -103.27% | |
| 17.93 | -829.93% | |
| -2.46 | -95.48% | |
| -54.29 | -26.18% | |
| -73.54 | -62.68% | |
| -197.04 | +118.82% | |
| -90.05 | +297.73% | |
| -22.64 | -86.04% | |
| -162.21 | +2,599.73% | |
| -6.01 | — |
Cartesian Therapeutics Stock analysis
Frequently Asked Questions about Cartesian Therapeutics stock
Interest Coverage Ratio of Cartesian Therapeutics is -88.50 in 2024.
Interest Coverage Ratio of Cartesian Therapeutics changed from -0.59 to -88.50, representing a 14,998.99% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Interest Coverage Ratio Cartesian Therapeutics since 2006 – with annual values, charts, and detailed analysis.
The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.
Interest Coverage = EBIT / Interest Expense
A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Cartesian Therapeutics with sector peers and the industry average to assess whether it is attractive.
Leverage — Cartesian Therapeutics
All Key Metrics — Cartesian Therapeutics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth